Literature DB >> 30511171

[Higher prevalence of depressive and anxiety symptoms in early arthritis patients in comparison to the normal population].

D Freier1, M Englbrecht2, V Höhne-Zimmer3, J Detert3, G-R Burmester3.   

Abstract

BACKGROUND: Many studies and registry data confirm that depression, often associated with anxiety disorders is very often found in patients with rheumatoid arthritis (RA). To what extent these psychiatric disorders are already relevant at a very early stage of the disease, has currently not been adequately investigated.
METHODS: In this study 176 patients with early joint symptoms (<1 year) were surveyed in an early arthritis consultation (EAC). The hospital anxiety and depression scale (HADS) was completed by the patients to examine the prevalence of depressive and anxiety symptoms. The results were compared to normative data of the general German population and between the diagnosis groups.
RESULTS: With 47.7% the prevalence of global distress for EA patients was almost twice as high compared to the corresponding group from the general population. This was also confirmed for depressive and anxiety symptoms. The EA patients without confirmed evidence of musculoskeletal inflammatory rheumatic disease (RD) showed nearly the same point prevalence as patients with confirmed RD. In multiple logistic regression the health assessment questionnaire (HAQ) was positively associated with global distress (odds ratio, OR 3.63) while the visual analogue scale (VAS) for global disease activity was positively associated with symptoms of depression (OR 1.03). Female EA patients (OR 5.45) appear to have a higher probability for experiencing corresponding symptoms, whereas patients over 60 years old appear to have less anxiety than younger patients (OR 0.11).
CONCLUSION: The high prevalence of symptoms of depression and anxiety in EA patients compared to the general population is a challenge for rheumatologists, orthopedists and general practitioners, particularly with respect to the differentiation of possible psychosomatic components in noninflammatory joint complaints. The results suggest that screening for psychiatric problems in patients with rheumatism should be evaluated as soon as possible as these can have a great impact on the perception of pain and physical functional status from the very beginning.

Entities:  

Keywords:  Anxiety; Depression; Early arthritis; HADS; Pain; Stress

Mesh:

Year:  2019        PMID: 30511171     DOI: 10.1007/s00393-018-0571-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  37 in total

Review 1.  The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders.

Authors:  C Heim; U Ehlert; D H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  2000-01       Impact factor: 4.905

2.  Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis.

Authors:  Chris Dickens; Linda McGowan; David Clark-Carter; Francis Creed
Journal:  Psychosom Med       Date:  2002 Jan-Feb       Impact factor: 4.312

3.  Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis.

Authors:  Frederick Wolfe; Kaleb Michaud; Theodore Pincus
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

4.  Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge.

Authors:  Matthias Englbrecht; Rieke Alten; Martin Aringer; Christoph G Baerwald; Harald Burkhardt; Nancy Eby; Gerhard Fliedner; Bettina Gauger; Ulf Henkemeier; Michael W Hofmann; Stefan Kleinert; Christian Kneitz; Klaus Krueger; Christoph Pohl; Anne-Eve Roske; Georg Schett; Marc Schmalzing; Anne-Kathrin Tausche; Hans Peter Tony; Joerg Wendler
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-01       Impact factor: 4.794

5.  Normative values for the hospital anxiety and depression scale (HADS) in the general German population.

Authors:  Andreas Hinz; Elmar Brähler
Journal:  J Psychosom Res       Date:  2011-03-02       Impact factor: 3.006

6.  Coping with rheumatoid arthritis pain in daily life: within-person analyses reveal hidden vulnerability for the formerly depressed.

Authors:  Tamlin S Conner; Howard Tennen; Alex J Zautra; Glenn Affleck; Stephen Armeli; Judith Fifield
Journal:  Pain       Date:  2006-08-14       Impact factor: 6.961

7.  Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis.

Authors:  Dennis C Ang; Hyon Choi; Kurt Kroenke; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-06       Impact factor: 4.666

8.  Identifying target areas of treatment for depressed early inflammatory arthritis patients.

Authors:  Patricia L Dobkin; Marta Filipski; Karl Looper; Orit Schieir; Murray Baron
Journal:  Psychother Psychosom       Date:  2008-07-04       Impact factor: 17.659

9.  Communication about depression during rheumatoid arthritis patient visits.

Authors:  Betsy Sleath; Betty Chewning; Brenda M de Vellis; Morris Weinberger; Robert F de Vellis; Gail Tudor; Ashley Beard
Journal:  Arthritis Rheum       Date:  2008-02-15

10.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

View more
  1 in total

1.  [Disease-related knowledge acquisition through structured patient information in rheumatoid arthritis (StruPI-RA) : First results of the StruPI-RA study in Germany].

Authors:  M Schwarze; V Fieguth; F Schuch; P Sandner; E Edelmann; A Händel; M Kettler; A Hanke; M Kück; L Stein; C Stille; M Fellner; V De Angelis; S Touissant; C Specker
Journal:  Z Rheumatol       Date:  2020-09-14       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.